1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pneumonia - Pipeline Review, H2 2013

Pneumonia - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 193 pages

Pneumonia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Pneumonia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pneumonia.
- A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pneumonia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pneumonia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Pneumonia - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pneumonia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pneumonia 9
Pneumonia Therapeutics under Development by Companies 11
Pneumonia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Pneumonia Therapeutics - Products under Development by Companies 19
Pneumonia Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Pneumonia Therapeutics Development 23
Shionogi and Co., Ltd. 23
Sanofi-Aventis 24
AstraZeneca PLC 25
Biotest AG 26
Dainippon Sumitomo Pharma Co., Ltd. 27
Rib-X Pharmaceuticals, Inc. 28
Cubist Pharmaceuticals, Inc. 29
Toyama Chemical Co. Ltd 30
Wockhardt Limited 31
Paratek Pharmaceuticals, Inc. 32
Bayer AG 33
Basilea Pharmaceutica Ltd. 34
Flamel Technologies S.A. 35
Dongwha Pharm Co., Ltd. 36
LTT Bio-Pharma Co., Ltd. 37
Synairgen plc 38
Mucosis B.V. 39
Aridis Pharmaceuticals LLC 40
aRigen Pharmaceuticals, Inc. 41
Sinovac Biotech Ltd. 42
KaloBios Pharmaceuticals, Inc. 43
Ancora Pharmaceuticals Inc. 44
KYORIN Pharmaceutical Co., Ltd. 45
Trius Therapeutics, Inc. 46
Tetraphase Pharmaceuticals Inc. 47
TaiGen Biotechnology Co., Ltd. 48
Savara, Inc. 49
Pulmotect, Inc. 50
Durata Therapeutics Inc. 51
APEPTICO Forschung und Entwicklung GmbH 52
Pneumonia - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
amikacin - Drug Profile 59
dalbavancin - Drug Profile 61
cethromycin - Drug Profile 63
omadacycline tosylate - Drug Profile 65
brilacidin - Drug Profile 68
PC-SOD - Drug Profile 70
pafuramidine - Drug Profile 71
AR-401 - Drug Profile 73
AR-101 - Drug Profile 74
AR-301 - Drug Profile 75
PAC-G31P - Drug Profile 76
Gyrase Program - Drug Profile 78
KRP-109 - Drug Profile 79
tedizolid phosphate - Drug Profile 80
tedizolid phosphate - Drug Profile 82
zabofloxacin - Drug Profile 84
nemonoxacin - Drug Profile 86
nemonoxacin - Drug Profile 88
(ceftolozane + tazobactam) - Drug Profile 90
interferon beta - Drug Profile 92
iseganan hydrochloride - Drug Profile 94
doripenem - Drug Profile 95
doripenem - Drug Profile 97
MAR Program - Drug Profile 99
tifacogin - Drug Profile 100
eravacycline - Drug Profile 101
ceftobiprole medocaril - Drug Profile 103
AZD-9742 - Drug Profile 105
(ceftazidime + avibactam) - Drug Profile 106
simvastatin - Drug Profile 108
AP-301 - Drug Profile 109
Pneumococcal Polysaccharides Vaccine - Drug Profile 111
MEDI-560 - Drug Profile 112
BT-086 - Drug Profile 113
Second Generation Ketolides - Drug Profile 114
vancomycin - Drug Profile 115
(eptifibatide + iloprost) - Drug Profile 117
SynGEM - Drug Profile 119
RX-P770 - Drug Profile 120
IMV-0123 - Drug Profile 122
tigecycline biobetter - Drug Profile 123
piperacillin sodium - Drug Profile 124
(amikacin + fosfomycin) - Drug Profile 125
MEDI-4893 - Drug Profile 126
PopB-Based Vaccine - Drug Profile 128
simvastatin - Drug Profile 129
Pseudomonas Aeruginosa Vaccine - Drug Profile 130
Vaccine For Moraxella catarrhalis - Drug Profile 131
MVX-507 - Drug Profile 132
SM-295291 - Drug Profile 133
SM-369926 - Drug Profile 134
iclaprim mesylate - Drug Profile 135
Pseudomonas aeruginosa Vaccine - Drug Profile 137
Pneumococcal Vaccine - Drug Profile 138
IkT-061 - Drug Profile 139
SAR-215500 - Drug Profile 140
ET-001 - Drug Profile 141
MAb Against S aureus - Drug Profile 142
Pneumonia Therapeutics - Drug Profile Updates 143
Pneumonia Therapeutics - Discontinued Products 179
Pneumonia Therapeutics - Dormant Products 180
Pneumonia - Product Development Milestones 181
Featured News and Press Releases 181
Appendix 188
Methodology 188
Coverage 188
Secondary Research 188
Primary Research 188
Expert Panel Validation 188
Contact Us 189
Disclaimer 189



List of Tables

Number of Products Under Development for Pneumonia, H2 2013 13
Products under Development for Pneumonia - Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2013 18
Comparative Analysis by Late Stage Development, H2 2013 19
Comparative Analysis by Mid Clinical Stage Development, H2 2013 20
Comparative Analysis by Early Clinical Stage Development, H2 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 22
Products under Development by Companies, H2 2013 23
Products under Development by Companies, H2 2013 (Contd..1) 24
Products under Development by Companies, H2 2013 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2013 26
Shionogi and Co., Ltd., H2 2013 27
Sanofi-Aventis, H2 2013 28
AstraZeneca PLC, H2 2013 29
Biotest AG, H2 2013 30
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 31
Rib-X Pharmaceuticals, Inc., H2 2013 32
Cubist Pharmaceuticals, Inc., H2 2013 33
Toyama Chemical Co. Ltd, H2 2013 34
Wockhardt Limited, H2 2013 35
Paratek Pharmaceuticals, Inc., H2 2013 36
Bayer AG, H2 2013 37
Basilea Pharmaceutica Ltd., H2 2013 38
Flamel Technologies S.A., H2 2013 39
Dongwha Pharm Co., Ltd., H2 2013 40
LTT Bio-Pharma Co., Ltd., H2 2013 41
Synairgen plc, H2 2013 42
Mucosis B.V., H2 2013 43
Aridis Pharmaceuticals LLC, H2 2013 44
aRigen Pharmaceuticals, Inc., H2 2013 45
Sinovac Biotech Ltd., H2 2013 46
Ancora Pharmaceuticals Inc., H2 2013 48
KYORIN Pharmaceutical Co., Ltd., H2 2013 49
Trius Therapeutics, Inc., H2 2013 50
Tetraphase Pharmaceuticals Inc., H2 2013 51
TaiGen Biotechnology Co., Ltd., H2 2013 52
Savara, Inc., H2 2013 53
Pulmotect, Inc., H2 2013 54
Durata Therapeutics Inc., H2 2013 55
APEPTICO Forschung und Entwicklung GmbH, H2 2013 56
Assessment by Monotherapy Products, H2 2013 57
Assessment by Combination Products, H2 2013 58
Assessment by Stage and Route of Administration, H2 2013 60
Assessment by Stage and Molecule Type, H2 2013 62
Pneumonia Therapeutics - Drug Profile Updates 147
Pneumonia Therapeutics - Discontinued Products 183
Pneumonia Therapeutics - Dormant Products 184



List of Figures

Number of Products under Development for Pneumonia, H2 2013 13
Products under Development for Pneumonia - Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 18
Late Stage Products, H2 2013 19
Mid Clinical Stage Products, H2 2013 20
Early Clinical Stage Products, H2 2013 21
Discovery and Pre-Clinical Stage Products, H2 2013 22
Assessment by Monotherapy Products, H2 2013 57
Assessment by Combination Products, H2 2013 58
Assessment by Route of Administration, H2 2013 59
Assessment by Stage and Route of Administration, H2 2013 60
Assessment by Molecule Type, H2 2013 61
Assessment by Stage and Molecule Type, H2 2013 62



Companies Mentioned

Shionogi and Co., Ltd.
Sanofi-Aventis
AstraZeneca PLC
Biotest AG
Dainippon Sumitomo Pharma Co., Ltd.
Rib-X Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
Toyama Chemical Co. Ltd
Wockhardt Limited
Paratek Pharmaceuticals, Inc.
Bayer AG
Basilea Pharmaceutica Ltd.
Flamel Technologies S.A.
Dongwha Pharm Co., Ltd.
LTT Bio-Pharma Co., Ltd.
Synairgen plc
Mucosis B.V.
Aridis Pharmaceuticals LLC
aRigen Pharmaceuticals, Inc.
Sinovac Biotech Ltd.
KaloBios Pharmaceuticals, Inc.
Ancora Pharmaceuticals Inc.
KYORIN Pharmaceutical Co., Ltd.
Trius Therapeutics, Inc.
Tetraphase Pharmaceuticals Inc.
TaiGen Biotechnology Co., Ltd.
Savara, Inc.
Pulmotect, Inc.
Durata Therapeutics Inc.
APEPTICO Forschung und Entwicklung GmbH

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.